Skip to content
lsd.com

Indication

Depressive Disorder, Treatment-Resistant

25 registered trials testing Psilocybin, Ketamine for this indication, 3 recruiting now.

Sponsors register this under 2 different names, all collected here: Depressive Disorder, Treatment-Resistant · Treatment Resistant Depressive Disorder

25
Registered trials
3
Recruiting
8
In Phase 3

Substances tested

Being studied with

Stay told

When a new trial opens

Research alerts

Get a notification when a trial for Depressive Disorder, Treatment-Resistant trials starts recruiting

This registry is rebuilt every day. If no trial is recruiting for you today, that can change within weeks.

This form sends your email address and the topic of this page to Brevo, our email provider, which stores them on servers in the European Union. We never sell that address, never share it with anyone, and never use it for advertising. One email deletes it. What is held, and where.

Trials

All 25 trials for Depressive Disorder, Treatment-Resistant

TrialStatusPhaseSubstanceSites
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant DepressionNCT07716098 · Janssen Research & Development, LLCRecruitingPhase 3ketamine4
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant DepressionNCT06511908 · National Institute of Mental Health (NIMH)RecruitingPhase 2ketamine1
Intravenous Ketamine for Treatment-Resistant DepressionNCT06668571 · Mayo ClinicRecruitingPhase 2ketamine1
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant DepressionNCT07053345 · Janssen Korea, Ltd., KoreaCompletedPhase 4ketamine6
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionNCT04599855 · Janssen Research & Development, LLCCompletedPhase 4ketamine54
Clinical Trial of the Use of Ketamine in Treatment Resistant DepressionNCT02610712 · National Institute of Neurology and Neurosurgery, MexicoUnknown statusPhase 4ketamine1
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant DepressionNCT02422186 · Janssen Research & Development, LLCCompletedPhase 3ketamine69
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLCCompletedPhase 3ketamine155
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLCCompletedPhase 3ketamine173
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT03434041 · Janssen Research & Development, LLCCompletedPhase 3ketamine30
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant DepressionNCT03852160 · Janssen-Cilag International NVWithdrawnPhase 3ketamine—
Ketamine for Treatment Resistant Late-Life DepressionNCT02556606 · VA Office of Research and DevelopmentCompletedPhase 3ketamine1
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal KetamineNCT04216888 · Dan IosifescuCompletedPhase 2 / Phase 3ketamine1
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressionNCT01998958 · Janssen Research & Development, LLCCompletedPhase 2ketamine25
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant DepressionNCT03756129 · Novartis PharmaceuticalsCompletedPhase 2ketamine12
Ketamine Infusions for PTSD and Treatment-Resistant DepressionNCT02577250 · Minneapolis Veterans Affairs Medical CenterCompletedPhase 1ketamine1
Glutamate and Opioid Mechanisms of Antidepressant Response to KetamineNCT04977674 · King's College LondonCompletedEarly Phase 1ketamine1
Behavioural Activation Therapy and Esketamine for Resistant DepressionNCT06431386 · The Royal's Institute of Mental Health ResearchTerminatedNot applicableketamine1
Effect of Psilocybin on the Positive Valence System in Treatment-resistant DepressionNCT06650800 · Centre Hospitalier Universitaire de NīmesCompletedNot applicablepsilocybin1
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)NCT03829579 · Janssen Research & Development, LLCApproved for marketingN/Aketamine—
Psilocybin-assisted Interpersonal Therapy for DepressionNCT05581797 · University of OtagoCompletedNot applicablepsilocybin1
Synaptic Imaging and Network Activity in Treatment Resistant DepressionNCT05870501 · King's College LondonCompletedNot applicableketamine1
Treatment Resistant Depression (Pilot)NCT01179009 · Washington University School of MedicineCompletedNot applicableketamine1
In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent CellsNCT05887310 · University of Milano BicoccaUnknown statusN/Aketamine1
Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in DepressionNCT04701866 · Douglas Mental Health University InstituteCompletedNot applicableketamine2

Records from ClinicalTrials.gov API v2, data build 2026-08-25. Indications are the sponsors’ own words. LSD.com reports registered clinical research. It is not medical advice, it is not a recommendation to take any substance, and trial listings are not endorsements. Talk to a clinician.